Advisory Board

Home / Advisory Board
The WinSanTor Advisory Board, WinSanTor’s Scientific and Technology Advisors provide diversified expertise across our external advisory network.

Peter C. Farrell,PhD,DSc,AM: Peter is the founding Executive Chairman and former Chief Executive Officer of ResMed, Inc., a leading developer and manufacturer of medical equipment for the diagnosis and treatment of sleep-disordered breathing. He held those positions from 1989 until 2007. Dr. Farrell holds bachelor’s and master’s degrees in Chemical Engineering from the University of Sydney and the Massachusetts Institute of Technology, a Ph.D. in Bioengineering from the University of Washington, Seattle, and a Doctor of Science from the University of New South Wales for research related to dialysis and renal medicine.


Marc Hodosh: Marc  is an American entrepreneur who most recently Co-Created and Hosted the TEDMED conference. Hodosh previously led the Archon Genomics X PRIZE. He has been a consultant to inventor Dean Kamen at DEKA Research & Development and is also Chairman of Kamen’s FIRST Robotics competition within the Boston region. Earlier, Mr. Hodosh founded and sold ID One, which specialized in facial recognition technology for the US Military and Intelligence communities. He also led business development at Viisage, a previously publicly traded, facial recognition company.Mr. Hodosh’s first business and entrepreneurial endeavors began by inventing and importing a variety of consumer products from Asia, with distribution through Bed Bath & Beyond, QVC television, Toys-R-Us, and others.


Rayaz Malik, PhD: Rayaz is a Professor of Medicine & Consultant Physician in the Division of Cardiovascular Medicine, Manchester Royal Infirmary & University of Manchester, Manchester. He is a consultant with responsibility for unselected general acute medicine admissions to Manchester Royal Infirmary and does a general medical and diabetes outpatient clinic weekly. His research focuses on diabetic neuropathy and cardiomyopathy in both animal models and most importantly at a translational level in patients. He is an expert in the pathogenesis, assessment and treatment of diabetic neuropathy and has published and presented extensively on this. His research is currently funded by the NIH, JDRF, MRC, DUK and BHF and he is currently supervising 6 PhD’s and 4 MD’s.


Dan Ross is the CEO of IMS Health Capital, Inc.: Dan leads a diverse team that supports and advises life sciences companies in their efforts to find partners, license assets, negotiate terms, and ultimately, move their exciting science more rapidly to the patient. He specializes in creating and programming complex financial, economic and “go/no go” models, valuing early-stage research opportunities, and assisting life sciences companies with business planning, partnership and collaboration negotiations, and mergers and acquisitions. He has experience in the therapeutic areas of oncology, orphan diseases, metabolism/obesity, infectious disease, neurology, women’s health and pain management.